New member: Hemispherian
In this article series, we will introduce the new members of our oncology cluster.
Our newest member Hemispherian is developing a better treatment option for patients with aggressive brain cancer.
Glioblastoma multiforme is one of the most aggressive types of cancer that begins within the brain. Current treatment options are limited to surgery, radiotherapy and chemotherapy, the median overall survival after diagnosis is only 15 months and is highly dependent on the success of the surgery.
A Norwegian company called Hemispherian is advancing a new method to treat glioblastoma multiforme. The molecules the company is developing are called GLIX1 and GLIX5. They target a mechanism that is unique to cancer cells and does not affect normal healthy cells. The molecules are highly toxic to cancer cells and have minimal side effects.
We talked to Adam Robertson, Chief Scientific Officer in Hemispherian, to find out more about the company and the research.
How is Hemispherian involved in health and cancer?
“We are advancing first-in-class therapeutics for the indication with the greatest unmet need in oncology — glioblastoma multiforme. Patients diagnosed with glioblastoma multiforme have dismal outcomes. Overall survival is measured in months with quality of life deteriorating rapidly. It is Hemispherian’s mission to provide superior treatment options.” Adam Robertson, Chief Scientific Officer, Hemispherian.
Why did Hemispherian become a member of Oslo Cancer Cluster?
“As a company focusing on developing cancer treatments Oslo Cancer Cluster is a natural fit for us. We are interested in Oslo Cancer Cluster’s extensive experience in the field and hope to benefit from advice and to make valuable contacts through Oslo Cancer Cluster’s network.” Adam Robertson, Chief Scientific Officer, Hemispherian.